{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T23:25:54Z","timestamp":1785281154207,"version":"3.55.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T00:00:00Z","timestamp":1643068800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.seizure.2022.01.011","type":"journal-article","created":{"date-parts":[[2022,1,22]],"date-time":"2022-01-22T02:11:52Z","timestamp":1642817512000},"page":"66-73","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Eye disorders associated with newer antiepileptic drugs: A real-world disproportionality analysis of FDA adverse event reporting system"],"prefix":"10.1016","volume":"96","author":[{"given":"Weiping","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinnan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.seizure.2022.01.011_bib0001","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S1474-4422(12)70153-9","article-title":"Adverse effects of antiepileptic drugs","volume":"11","author":"Perucca","year":"2012","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.1016\/j.seizure.2022.01.011_bib0002","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1080\/17512433.2019.1591274","article-title":"Ocular dysfunctions and toxicities induced by antiepileptic medications: types, pathogenic mechanisms, and treatment strategies","volume":"12","author":"Hamed","year":"2019","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.seizure.2022.01.011_bib0003","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1212\/WNL.0000000000005755","volume":"91","author":"Kanner","year":"2018","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.seizure.2022.01.011_bib0004","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1212\/WNL.0000000000005756","volume":"91","author":"Kanner","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2022.01.011_bib0005","unstructured":"FDA. Drugs@FDA: FDA-approved drugs. 2021 01\/2021]; Available from: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm."},{"key":"10.1016\/j.seizure.2022.01.011_bib0006","unstructured":"FDA Adverse Event Reporting System (FAERS): Latest quarterly data files. 2018 08\/03\/2018 [cited 2018 08\/03]; Available from: https:\/\/www.fda.gov\/drugs\/questions-and-answers-fdas-adverse-event-reporting-system-faers\/fda-adverse-event-reporting-system-faers-latest-quarterly-data-files."},{"key":"10.1016\/j.seizure.2022.01.011_bib0007","doi-asserted-by":"crossref","unstructured":"Shen, B., <Healthcare+and+Big+Data+Management.pdf>. Vol. 1028. 2017.","DOI":"10.1007\/978-981-10-6041-0"},{"issue":"6","key":"10.1016\/j.seizure.2022.01.011_bib0008","doi-asserted-by":"crossref","first-page":"425","DOI":"10.2515\/therapie\/2008069","article-title":"[Antiepileptic drugs]","volume":"63","author":"G\u00e9lisse","year":"2008","journal-title":"Therapie"},{"issue":"4","key":"10.1016\/j.seizure.2022.01.011_bib0009","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.ncl.2010.03.026","article-title":"The selection of antiepileptic drugs for the treatment of epilepsy in children and adults","volume":"28","author":"Asconap\u00e9","year":"2010","journal-title":"Neurol Clin"},{"issue":"7","key":"10.1016\/j.seizure.2022.01.011_bib0010","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.ophtha.2003.12.052","article-title":"Adverse ocular drug reactions recently identified by the national registry of drug-induced ocular side effects","volume":"111","author":"Fraunfelder","year":"2004","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.seizure.2022.01.011_bib0011","doi-asserted-by":"crossref","first-page":"501","DOI":"10.2165\/11533180-000000000-00000","article-title":"Ocular adverse effects of common psychotropic agents: a review","volume":"24","author":"Richa","year":"2010","journal-title":"CNS Drugs"},{"key":"10.1016\/j.seizure.2022.01.011_bib0012","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2147\/OPTH.S27695","article-title":"Topiramate and the vision: a systematic review","volume":"6","author":"Abtahi","year":"2012","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"10.1016\/j.seizure.2022.01.011_bib0013","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0002-9394(01)01013-3","article-title":"Presumed topiramate-induced bilateral acute angle-closure glaucoma","volume":"132","author":"Banta","year":"2001","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"10.1016\/j.seizure.2022.01.011_bib0014","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S1059-1311(03)00082-7","article-title":"The effect of antiepileptic drugs on visual performance","volume":"13","author":"Hilton","year":"2004","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2022.01.011_bib0015","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13256-016-0980-x","article-title":"Presumed topiramate retinopathy: a case report","volume":"10","author":"Yeung","year":"2016","journal-title":"J Med Case Rep"},{"key":"10.1016\/j.seizure.2022.01.011_bib0016","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ajoc.2017.05.005","article-title":"Topiramate-induced macular neurosensory retinal detachment","volume":"7","author":"Rosenberg","year":"2017","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"12","key":"10.1016\/j.seizure.2022.01.011_bib0017","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.oftal.2019.07.014","article-title":"Macular neurosensory retinal detachment associated with topiramate use","volume":"94","author":"Mu\u00f1oz Morales","year":"2019","journal-title":"Arch Soc Esp Oftalmol"},{"issue":"6","key":"10.1016\/j.seizure.2022.01.011_bib0018","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.survophthal.2017.05.001","article-title":"Exudative retinal detachment","volume":"62","author":"Amer","year":"2017","journal-title":"Surv Ophthalmol"},{"issue":"8","key":"10.1016\/j.seizure.2022.01.011_bib0019","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.ophtha.2020.04.044","article-title":"Topiramate-induced choroidal effusions","volume":"127","author":"Subramanian","year":"2020","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.seizure.2022.01.011_bib0020","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3109\/09273948.2010.523805","article-title":"Topiramate-induced bilateral anterior uveitis associated with hypopyon formation","volume":"19","author":"Jabbarpoor Bonyadi","year":"2011","journal-title":"Ocul Immunol Inflamm"},{"issue":"5","key":"10.1016\/j.seizure.2022.01.011_bib0021","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1055\/s-2006-926600","article-title":"Blood-brain barrier disruption associated with topiramate-induced angle-closure glaucoma of acute onset","volume":"223","author":"Viet Tran","year":"2006","journal-title":"Klin Monbl Augenheilkd"},{"issue":"2","key":"10.1016\/j.seizure.2022.01.011_bib0022","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/ICL.0000000000000157","article-title":"Topiramate-induced changes in anterior chamber angle and choroidal thickness","volume":"42","author":"Karalezli","year":"2016","journal-title":"Eye Contact Lens"},{"issue":"4","key":"10.1016\/j.seizure.2022.01.011_bib0023","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/15569527.2017.1311337","article-title":"Effect of topiramate on choroidal thickness and anterior chamber parameters in the treatment of patients with migraine","volume":"36","author":"Gok","year":"2017","journal-title":"Cutan Ocul Toxicol"},{"issue":"5","key":"10.1016\/j.seizure.2022.01.011_bib0024","first-page":"338","article-title":"Lid lag and lagophthalmos: a clarification of terminology","volume":"12","author":"Harvey","year":"1981","journal-title":"Ophthalmic Surg"},{"issue":"6","key":"10.1016\/j.seizure.2022.01.011_bib0025","first-page":"591","article-title":"Graves' ophthalmopathy","volume":"158","author":"Barrie","year":"1993","journal-title":"West J Med"},{"issue":"6","key":"10.1016\/j.seizure.2022.01.011_bib0026","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.seizure.2009.02.003","article-title":"Retinal ganglion cell toxicity due to oxcarbazepine and valproic acid treatment in rat","volume":"18","author":"Akta\u015f","year":"2009","journal-title":"Seizure"},{"issue":"2","key":"10.1016\/j.seizure.2022.01.011_bib0027","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/j.1875-9114.1995.tb04346.x","article-title":"Lamotrigine","volume":"15","author":"Burstein","year":"1995","journal-title":"Pharmacotherapy"},{"issue":"1","key":"10.1016\/j.seizure.2022.01.011_bib0028","first-page":"6","article-title":"COGAN'S syndrome","volume":"59","author":"Iliescu","year":"2015","journal-title":"Rom J Ophthalmol"},{"key":"10.1016\/j.seizure.2022.01.011_bib0029","series-title":"in uveitis","first-page":"41","article-title":"3 - examination of the patient with uveitis","author":"Whitcup","year":"2010"},{"issue":"7","key":"10.1016\/j.seizure.2022.01.011_bib0030","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1111\/j.1528-1167.2005.43204.x","article-title":"Retinal electrophysiological results in patients receiving lamotrigine monotherapy","volume":"46","author":"Arndt","year":"2005","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.seizure.2022.01.011_bib0031","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.annder.2010.10.029","article-title":"Stevens-Johnson and Lyell syndromes: mucocutaneous and ocular sequels in 43 cases","volume":"138","author":"Fellahi","year":"2011","journal-title":"Ann Dermatol Venereol"},{"issue":"5","key":"10.1016\/j.seizure.2022.01.011_bib0032","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s00381-019-04076-5","article-title":"An investigation of the ocular toxic effects of levetiracetam therapy in children with epilepsy","volume":"35","author":"Diler Durgut","year":"2019","journal-title":"Childs Nerv Syst"},{"issue":"3","key":"10.1016\/j.seizure.2022.01.011_bib0033","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S1059-1311(03)00193-6","article-title":"Efficacy and tolerability of levetiracetam in children aged 10 years and younger: a clinical experience","volume":"13","author":"Tan","year":"2004","journal-title":"Seizure"},{"issue":"3","key":"10.1016\/j.seizure.2022.01.011_bib0034","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/IIO.0000000000000274","article-title":"Papilledema","volume":"59","author":"Chen","year":"2019","journal-title":"Int Ophthalmol Clin"},{"issue":"2","key":"10.1016\/j.seizure.2022.01.011_bib0035","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/ane.12922","article-title":"Intracranial pressure in patients with papilloedema","volume":"138","author":"Funnell","year":"2018","journal-title":"Acta Neurol Scand"},{"issue":"6","key":"10.1016\/j.seizure.2022.01.011_bib0036","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1002\/ana.410410620","article-title":"A double-blind controlled study of gabapentin and baclofen as treatment for acquired nystagmus","volume":"41","author":"Averbuch-Heller","year":"1997","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1016\/j.seizure.2022.01.011_bib0037","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3109\/01658109609009669","article-title":"A pilot study of gabapentin as treatment for acquired nystagmus","volume":"16","author":"Stahl","year":"1996","journal-title":"Neuroophthalmology"},{"key":"10.1016\/j.seizure.2022.01.011_bib0038","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3389\/fphar.2017.00173","article-title":"Gabapentin Attenuates Ocular inflammation: in vitro and in vivo studies","volume":"8","author":"Anfuso","year":"2017","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.seizure.2022.01.011_bib0039","series-title":"in retina","first-page":"1306","article-title":"Chapter 73 - uveal Effusion syndrome and hypotony maculopathy","author":"Besirli","year":"2013"},{"issue":"6","key":"10.1016\/j.seizure.2022.01.011_bib0040","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/j.1600-0420.2007.00910.x","article-title":"Hypotony maculopathy","volume":"85","author":"Costa","year":"2007","journal-title":"Acta Ophthalmol Scand"},{"issue":"5","key":"10.1016\/j.seizure.2022.01.011_bib0041","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0039-6257(97)00132-X","article-title":"Macular hole","volume":"42","author":"Ho","year":"1998","journal-title":"Surv Ophthalmol"},{"issue":"5","key":"10.1016\/j.seizure.2022.01.011_bib0042","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s00347-012-2555-6","article-title":"Retinitis pigmentosa - a review. Pathogenesis, guidelines for diagnostics and perspectives","volume":"109","author":"Zobor","year":"2012","journal-title":"Ophthalmologe"},{"issue":"1","key":"10.1016\/j.seizure.2022.01.011_bib0043","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/WCO.0b013e328341e3b5","article-title":"Oscillopsia: causes and management","volume":"24","author":"Tilikete","year":"2011","journal-title":"Curr Opin Neurol"},{"issue":"11","key":"10.1016\/j.seizure.2022.01.011_bib0044","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1345\/aph.1M303","article-title":"Lacosamide: an adjunctive agent for partial-onset seizures and potential therapy for neuropathic pain","volume":"43","author":"Harris","year":"2009","journal-title":"Ann Pharmacother"},{"issue":"12","key":"10.1016\/j.seizure.2022.01.011_bib0045","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/s40263-013-0123-5","article-title":"Lacosamide: a review of its use as adjunctive therapy in the management of partial-onset seizures","volume":"27","author":"Hoy","year":"2013","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1016\/j.seizure.2022.01.011_bib0046","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1080\/14740338.2020.1713089","article-title":"The adverse-effect profile of lacosamide","volume":"19","author":"Li","year":"2020","journal-title":"Expert Opin Drug Saf"},{"issue":"7","key":"10.1016\/j.seizure.2022.01.011_bib0047","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1097\/IAE.0000000000000581","article-title":"Metamorphopsia and its quantification","volume":"35","author":"Simunovic","year":"2015","journal-title":"Retina"},{"issue":"7","key":"10.1016\/j.seizure.2022.01.011_bib0048","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.7150\/ijms.34141","article-title":"Torsades de pointes and QT prolongation associations with antibiotics: a pharmacovigilance study of the FDA adverse event reporting system","volume":"16","author":"Teng","year":"2019","journal-title":"Int J Med Sci"}],"container-title":["Seizure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131122000115?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131122000115?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T02:00:15Z","timestamp":1761012015000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131122000115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":48,"alternative-id":["S1059131122000115"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2022.01.011","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Eye disorders associated with newer antiepileptic drugs: A real-world disproportionality analysis of FDA adverse event reporting system","name":"articletitle","label":"Article Title"},{"value":"Seizure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2022.01.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd on behalf of British Epilepsy Association.","name":"copyright","label":"Copyright"}]}}